Advancements in ROS1-Positive Non-Small Cell Lung CancerA recent article from CURE Today highlights the progress being made in targeted therapies for this rare subtype of lung cancer, which affects around 1-2% of patients.
Our West family is proud to be at the forefront of this critical work, where Dr. Jason Porter and his team are leading efforts to bring innovative treatments and cutting-edge clinical trials to patients. 
Dr. Porter’s dedication to improving outcomes for lung cancer patients is making a real difference, offering new hope through precision medicine and personalized care.